Clinical experience with etidronate in osteoporosis

Area of Science:

• Bone Biology and Metabolism
• Pharmacology and Therapeutics

Background:

• Osteoporosis is a significant public health concern characterized by low bone mass and microarchitectural deterioration.
• Bisphosphonates, such as etidronate, are a cornerstone in osteoporosis management.

Purpose of the Study:

• To evaluate the clinical efficacy and patient response to cyclical etidronate therapy for osteoporosis.
• To assess changes in bone mineral density (BMD) at various skeletal sites.

Main Methods:

• Retrospective review of 69 consecutive patients treated with cyclical etidronate.
• Bone mineral density (BMD) measurements using dual-energy X-ray absorptiometry (DXA) before and after 1 year of treatment.
• Analysis of BMD changes in subgroups with osteoporotic fractures and osteopenia.

Main Results:

• BMD increased by 4.50% in the lumbar spine (p < 0.001) and 5.5% at Ward's triangle (p < 0.01) after 1 year.
• No significant BMD changes were observed at the femoral neck or greater trochanter.
• 83% of patients showed increased lumbar spine BMD, and 55% had increased femoral neck BMD after 1 year.

Conclusions:

• Cyclical etidronate therapy demonstrates efficacy in preserving and increasing bone mass in the majority of osteoporosis patients.
• A wide variation in BMD response exists, with a minority of patients not experiencing bone mass increase.
• The therapy is generally well-tolerated, with few discontinuations due to adverse effects.